Myelodysplastic/Myeloproliferative Neoplasms Clinical Trials

6 recruitingLast updated: June 18, 2026

There are 6 actively recruiting myelodysplastic/myeloproliferative neoplasms clinical trials across 3 countries. Studies span Phase 2, Phase 1. Top locations include Chapel Hill, North Carolina, United States, Hendersonville, North Carolina, United States, Detroit, Michigan, United States. Updated daily from ClinicalTrials.gov.


Myelodysplastic/Myeloproliferative Neoplasms Trials at a Glance

6 actively recruiting trials for myelodysplastic/myeloproliferative neoplasms are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Chapel Hill, Hendersonville, and Detroit. Lead sponsors running myelodysplastic/myeloproliferative neoplasms studies include UNC Lineberger Comprehensive Cancer Center, Barbara Ann Karmanos Cancer Institute, and Jubilant Therapeutics Inc..

Browse myelodysplastic/myeloproliferative neoplasms trials by phase

Treatments under study

About Myelodysplastic/Myeloproliferative Neoplasms Clinical Trials

Looking for clinical trials for Myelodysplastic/Myeloproliferative Neoplasms? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myelodysplastic/Myeloproliferative Neoplasms trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myelodysplastic/Myeloproliferative Neoplasms clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1Phase 2

Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis

Myeloproliferative Neoplasms (MPN)Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)Essential Thrombocythemia, ET
Jubilant Therapeutics Inc.30 enrolled7 locationsNCT07612280
Recruiting

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

LymphomaLeukemiaMyelodysplastic Syndromes+5 more
UNC Lineberger Comprehensive Cancer Center15,000 enrolled1 locationNCT01137643
Recruiting

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

LymphomaUnspecified Adult Solid Tumor, Protocol SpecificLeukemia+6 more
Barbara Ann Karmanos Cancer Institute1 locationNCT00935090
Recruiting

OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study

MDSMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms+1 more
Sunnybrook Health Sciences Centre60 enrolled1 locationNCT06270771
Recruiting

Registry of Older Patients With Cancer

LymphomaUnspecified Adult Solid Tumor, Protocol SpecificLeukemia+6 more
UNC Lineberger Comprehensive Cancer Center3,000 enrolled7 locationsNCT01137825
Recruiting
Phase 2

Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects with Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) with Thrombocytosis.

Myeloproliferative Neoplasms (MPN)Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)
Jubilant Therapeutics, Inc.30 enrolled3 locationsACTRN12624000478516